The OTHER Janssen Agreement
Posted: Mon Sep 17, 2018 4:34 pm
As is common knowledge, Janssen and Geron have a second license agreement signed following the imetelstat collaboration agreement. Janssen licensed additional patents and rights from Geron to develop new drugs outside the field of telomerase inhibition. The agreement provides for annual license fees, as well as confidential milestone payments for various drug development milestones and royalties on commercial sales. Janssen is required to provide Geron with an annual report of research activities on the anniversary of the agreement, which was September 15. So, in addition to working on the continuation decision from the imetelstat agreement, Janssen also needed to report on its activities under the second license agreement as well. https://www.sec.gov/Archives/edgar/data/886744/000110465916154548/a16-17207_1ex10d1.htm